SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-22-000033
Filing Date
2022-03-10
Accepted
2022-03-10 07:39:45
Documents
17
Period of Report
2022-03-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20220308.htm   iXBRL 8-K 49990
2 EX-99.1 exh991q42021earningsrelease.htm EX-99.1 99106
3 EX-99.2 exh992hayfin.htm EX-99.2 18834
8 image_0.jpg GRAPHIC 18252
9 picture1reviseda.jpg GRAPHIC 4446
  Complete submission text file 0001867096-22-000033.txt   395821

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20220308.xsd EX-101.SCH 2153
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20220308_def.xml EX-101.DEF 15449
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20220308_lab.xml EX-101.LAB 29866
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20220308_pre.xml EX-101.PRE 16118
11 EXTRACTED XBRL INSTANCE DOCUMENT xers-20220308_htm.xml XML 11567
Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 22727433
SIC: 2834 Pharmaceutical Preparations